Review
Open access
Aug 2026
A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran
Inclisiran may represent another milestone in the treatment of dyslipidemia, and the associated mechanism of action, pharmacology, clinical trial data, efficacy, safety, use in special populations, and adverse effects are comprehensively discussed.
Xue-Bing Wu, Jing Zhang
· Reviews in cardiovascular me... · 0 citations